Hemab Therapeutics Holdings (COAG) CMO receives new option and warrant grants

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. reported that Chief Medical Officer Catherine Madigan received new equity awards. She was granted 145,134 warrants to buy common stock at $6.00 per share, expiring on January 28, 2036. The shares underlying this warrant vest over four years, with 25% vesting on January 1, 2027 and the remainder in equal monthly installments.

Madigan was also granted a stock option for 49,016 shares of common stock at an exercise price of $18.00 per share, expiring on April 29, 2036. These option shares vest in equal monthly installments over four years from May 1, 2026 through May 1, 2030. Both awards are structured as long-term compensation rather than open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Madigan Catherine

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	49,016	$0.00	--
Grant/Award	Warrants (Right to Buy)	145,134	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 49,016 shares (Direct, null); Warrants (Right to Buy) — 145,134 shares (Direct, null)

Footnotes (1)

1. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter. This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.

Key Figures

Warrant grant size: 145,134 warrants Warrant exercise price: $6.00 per share Warrant expiration: January 28, 2036 +5 more

8 metrics

Warrant grant size 145,134 warrants Granted January 29, 2026 to CMO

Warrant exercise price $6.00 per share Warrants for common stock expiring January 28, 2036

Warrant expiration January 28, 2036 End of exercise period for 145,134-share warrant

Stock option grant size 49,016 options Granted April 30, 2026 to CMO

Stock option exercise price $18.00 per share Options for common stock expiring April 29, 2036

Option expiration April 29, 2036 End of exercise period for 49,016 options

Vesting start for options May 1, 2026 Monthly vesting through May 1, 2030

Cliff vesting date for warrants January 1, 2027 25% of warrant shares vest on this date

Key Terms

Stock Option (Right to Buy), Warrants (Right to Buy), vest, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) for 49,016 shares at $18.00"

Warrants (Right to Buy) financial

"security_title: Warrants (Right to Buy) for 145,134 shares at $6.00"

vest financial

"The shares underlying the warrant vest over four years, with 25% vesting on January 1, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 18.0000 and 6.0000 indicate the exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Madigan Catherine

(Last) (First) (Middle)

C/O HEMAB THERAPEUTICS HOLDINGS, INC.

101 MAIN STREET, SUITE 1220

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$6	01/29/2026		A		145,134		(1)	01/28/2036	Common Stock	145,134	$0	145,134	D
Stock Option (Right to Buy)	$18	04/30/2026		A		49,016		(2)	04/29/2036	Common Stock	49,016	$0.00	49,016	D

Explanation of Responses:

1. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.

2. This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.

	/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Hemab Therapeutics (COAG) report for Catherine Madigan?

Catherine Madigan received two equity grants: a warrant for 145,134 shares at $6.00 and a stock option for 49,016 shares at $18.00. Both are derivative awards used as long-term compensation rather than open-market share purchases or sales.

What are the terms of the new warrants granted to Hemab Therapeutics (COAG) CMO?

The warrant covers 145,134 common shares at a $6.00 exercise price, expiring January 28, 2036. The underlying shares vest over four years, with 25% vesting January 1, 2027 and the rest in equal monthly installments thereafter.

How do the new stock options for Hemab Therapeutics (COAG) CMO vest?

The 49,016 stock options vest monthly over four years. They were granted April 30, 2026 and vest in equal monthly installments from May 1, 2026 through May 1, 2030, at an exercise price of $18.00 per share, expiring April 29, 2036.

Are the Hemab Therapeutics (COAG) insider transactions open-market buys or compensation grants?

Both transactions are compensation-related grants, not open-market trades. The Form 4 classifies them as grant or award acquisitions of derivative securities (options and warrants) with specified exercise prices and long-term vesting schedules for the Chief Medical Officer.

What is the significance of the expiration dates on Hemab Therapeutics (COAG) CMO’s new awards?

The awards have long-dated expirations in 2036, giving the CMO an extended window to exercise if vesting and other conditions are met. The warrant expires January 28, 2036, while the stock option expires April 29, 2036, supporting long-term incentive alignment.